返回 
加入收藏
酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析 |
| TITLE： | Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer |
| 摘要： | 目的 分析酪氨酸激酶抑制剂（TKIs）治疗人表皮生长因子受体2（HER2）阳性乳腺癌的研究现状、热点和发展趋势。方法在WebofScience核心合集数据库中检索TKIs治疗HER2阳性乳腺癌的相关文献，使用CiteSpace6.1.R3软件对发文作者、国家/地区、机构、学科领域、期刊、关键词进行可视化分析。结果共纳入732篇文献，发文量呈逐年上升趋势，以美国发文最多（中心度0.10），我国发文量排第2位（中心度0.05）。发文量和被引频次最多的作者分别是澳大利亚圣文森特大学医院的Crown和美国加州大学洛杉矶分校的Slamon；发文量最多的机构是美国得克萨斯大学安德森癌症中心，最多的期刊是美国JournalofClinicalOncology；研究热点主要集中在HER2阳性乳腺癌治疗药物、TKIs作用受体、TKIs作用机制、HER2阳性乳腺癌脑转移、TKIs临床研究5个方面；前沿领域和发展趋势主要为TKIs与其他药物或治疗手段联用以增强靶向性并降低毒副作用。结论TKIs治疗HER2阳性乳腺癌的研究受到国内外学者的重视。我国学者和研究团队未来需要加强合作交流，可从TKIs单用及联合用药治疗HER2阳性乳腺癌的疗效及安全性方面加强与其他国家的合作。 |
| ABSTRACT： | OBJECTIVE To analyze the research status， hotspot and development trend of tyrosine kinase inhibitors （TKIs） in the treatment of human epidermal growth factor receptor 2 （HER2） positive breast cancer. METHODS The literature related to TKIs in the treatment of HER2 positive breast cancer were searched from the Web of Science core collection database； the author， country/region， institution， subject field， journal and keywords was visualized by CiteSpace 6.1.R3 software. RESULTS A total of 732 pieces of literature were included， and the number of literature published showed an increasing trend year by year. The number of literature published in the United States was the largest （center degree 0.10）， and the number of literature published in China ranked second （center degree 0.05）. The most published and cited authors were Crown from St. Vincent’s University Hospital in Australia and Slamon from University of California， Los Angeles in the United States； the institution with the highest number of literature was the University of Texas MD Anderson Cancer Center， and the journal with the highest number of literature was the Journal of Clinical Oncology. The research mainly focused on five aspects： HER2 positive breast cancer treatment drugs， TKIs receptor， TKIs mechanism of action， HER2 positive breast cancer brain metastasis， and TKIs clinical trials. The main frontier areas and development trends were the combination of TKIs with other drugs or therapies to enhance targeting and reduce toxic side effects. CONCLUSIONS The study of TKIs in the treatment of HER2 positive breast cancer has attracted the attention of scholars at home and abroad. Chinese scholars and research teams need to strengthen cooperation and communication in the future， and cooperation with other countries should be strengthened in terms of the efficacy and safety of TKIs alone and combined with other drugs in the treatment of HER2 positive breast cancer. |
| 期刊： | 2023年第34卷第24期 |
| 作者： | 邹婧；楚尧娟；杜秋争；岳鹤影；王小宝；杜书章 |
| AUTHORS： | ZOU Jing，CHU Yaojuan，DU Qiuzheng，YUE Heying，WANG Xiaobao，DU Shuzhang |
| 关键字： | 酪氨酸激酶抑制剂；人表皮生长因子受体-2阳性乳腺癌；可视化分析 |
| KEYWORDS： | tyrosine kinase inhibitors； human epidermal growth factor receptor-2 positive breast cancer； visual analysis |
| 阅读数： | 54 次 |
| 本月下载数： | 7 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
